SIHUAN PHARM (00460.HK) repurchases 5 million shares at HK$0.7019 average for HK$3.51 million
NewTimeSpace News: On November 20, 2026, Sihuan Pharmaceutical Holdings Group Ltd. (00460.HK) announced that, pursuant to the general mandate granted by shareholders at the annual general meeting held on June 26, 2026, it repurchased a total of 5,000,000 shares on the market on November 20 at an average price of HK$0.7019 per share, for a total consideration (excluding commission and other expenses) of approximately HK$3,509,500.
The repurchased shares represented approximately 0.0549% of the company's total issued shares (excluding treasury shares). The company will hold the shares as treasury shares and intends to use them for subsequent sale or transfer. The board considers that the current share price does not fully reflect the company's intrinsic value, and that the repurchase demonstrates confidence in business development and safeguards shareholders' interests.
In the first half of 2026, the group recorded revenue of RMB1.161 billion, up 1.3% year on year, and net profit of RMB212 million, up 221%. Revenue of the medical aesthetics business reached RMB693 million, up 18.5%, with more than 9,000 partner medical aesthetics institutions.
- SIHUAN PHARM (00460.HK): Bireociclib Adds First-Line NRDL Cover
- SIHUAN PHARM (00460.HK): bireociclib indication added to national NRDL
- SIHUAN PHARM (00460.HK): Xuanzhu Bio's Phase III Anlarazole Data Presented at UEG Week
- SIHUAN PHARM (00460.HK): Two aesthetics products approved in HK
- SIHUAN PHARM (00460.HK): Dongyan skin booster gets five new specs in China